Your session is about to expire
← Back to Search
Part 1: Gantenerumab for Alzheimer's Disease (DIAN-TU Trial)
DIAN-TU Trial Summary
This trial will study if treatment with an investigational study drug can prevent or slow the rate of Alzheimer's disease (AD)-causing accumulation of amyloid beta (Aβ). Part 1 will use Aβ positron emission tomography (PET) imaging to determine if treatment with the study drug prevents or slows the rate of Aβ pathological disease accumulation. Part 2 will evaluate the effect of early Aβ plaque reduction/prevention on disease progression by assessing downstream non-Aβ biomarkers of AD.
- Familial Alzheimer Disease
- Dementia
- Alzheimer's Disease
DIAN-TU Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2021 Phase 3 trial • 389 Patients • NCT02051608DIAN-TU Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
Are there any available positions for participants in this clinical trial?
"Unfortunately, this particular clinical trial is not enrolling participants at the moment. Although, it was last updated on September 22nd, 2022 and 783 other trials are actively looking for candidates."
Are there multiple testing sites for this new treatment?
"This trial has 16 enrolling sites, with locations including Dallas, Atlanta and Birmingham."
Share this study with friends
Copy Link
Messenger